Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.92M | -12.26M | -10.54M | -10.64M | -10.68M |
| Total Depreciation and Amortization | 412.50K | 415.70K | 417.80K | 427.50K | 434.90K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 822.60K | 536.00K | 242.10K | 297.20K | 348.80K |
| Change in Net Operating Assets | 1.38M | 1.00M | 603.90K | 189.40K | -222.40K |
| Cash from Operations | -11.30M | -10.31M | -9.27M | -9.73M | -10.12M |
| Capital Expenditure | -7.40K | -8.50K | -9.60K | -70.70K | -131.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -7.40K | -8.50K | -9.60K | -70.70K | -131.30K |
| Total Debt Issued | 1.65M | 826.00K | -- | -- | -- |
| Total Debt Repaid | -964.00K | -702.00K | -440.00K | -433.50K | -427.00K |
| Issuance of Common Stock | 22.98M | 16.98M | 10.97M | 7.94M | 4.91M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.93M | -1.59M | -1.25M | -975.00K | -700.00K |
| Cash from Financing | 15.80M | 11.39M | 6.85M | 4.84M | 2.80M |
| Foreign Exchange rate Adjustments | 399.40K | 231.20K | 58.40K | -3.90K | -66.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.89M | 1.30M | -2.37M | -4.96M | -7.52M |